Pfizer Inc. (NYSE:PFE) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 16, Pfizer Inc. (NYSE ...
Pfizer Inc. (NYSE:PFE) is one of the best affordable healthcare stocks to buy now. Scotiabank analyst Louise Chen reiterated ...
MarketBeat on MSN
Why Wall Street gave up on Pfizer - and why that may be a mistake
The market of 2025 will be remembered for its extremes. While investors poured billions into technology sector giants and ...
A patient died after receiving Pfizer Inc.’s drug for hemophilia, marking another setback for the company in the treatment of ...
Pfizer Inc. forecast little to no sales growth next year as the drugmaker undertakes an effort to refresh its pipeline of hit drugs with a series of pricey acquisitions.
In a significant move for investors, Brookstone Capital Management has increased its stake in Pfizer Inc. (NYSE:PFE) by a staggering 134.1%, now holding 269,381 shares valued at $6.86 million. This ...
Investing.com -- A patient died after receiving Pfizer Inc.’s (NYSE:PFE) hemophilia drug Hympavzi, adding to challenges for ...
Pfizer disclosed a patient death in a marstacimab hemophilia study, triggering a safety review and reassessment of surgical ...
Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click for this updated look at PFE stock.
Discover why Pfizer (PFE) remains a compelling income opportunity with a 7% yield, robust cash flow, and long-term growth ...
Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer shed light on. During the lightning round, a caller sought Cramer’s opinion on the stock, and he said: “Okay, Pfizer, really good yield, not a ...
The stock's Price to Earnings ratio of 14.56 is lower than the industry average by 0.24x, suggesting potential value in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback